SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

LUNRs sharp rebound is being linked to NASAs CLPS 2 lunar-services awards, with traders pointing to claims of a company selection while others question whether the news is confirmed or priced in. The move has intensified debate over short covering and whether the rally can hold ahead of earnings.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Interim ARO-MAPT results showing a substantial reduction in spinal-fluid tau in healthy volunteers have focused attention on Arrowheads potential subcutaneous RNAi delivery to the brain. Many traders view the data as a validation of the platform, while others note that clinical benefit in patients remains unproven and are frustrated by the stocks muted reaction.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

ETs latest earnings update is drawing attention: traders note an earnings miss alongside higher full-year EBITDA guidance, with some viewing the stronger outlook as supportive and others questioning the muted performance. The pullback is also being attributed to higher interest rates and borrowing costs, while investors debate whether data-center gas demand can drive further growth.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO is drawing attention as traders use the leveraged inverse crude ETF to bet on oils direction amid shifting Iran and Strait of Hormuz conflict and peace-deal expectations. Some expect de-escalation and lower oil prices to lift SCO, while others complain that futures exposure, backwardation and daily-reset decay have caused it to lag crudes moves.

Victoria's Secret & Co. operates as a lingerie, clothing and beauty retailer. It offers bras, panties, lingerie, sleepwear, apparel, sport and swim apparel, and beauty products. The company was founded in 1963 and is headquartered in Reynoldsburg, OH.

Victoria`s Secret & Co

Victorias Secrets strong quarterly results and raised full-year outlook, attributed to improving demand and its turnaround strategy, have fueled a sharp rally and talk of short covering. Bulls see renewed brand momentum, while bears argue the surge has outpaced the companys fundamentals and may be unsustainable.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Debate over Johnson & Johnsons bleximenib AML data is driving attention, with traders weighing whether it threatens Kuras ziftomenib in frontline treatment and questioning how comparable the patient groups are. Some view the competitive news as an overreaction, pointing to KOMZIFTIs launch progress and upcoming clinical updates; others see a meaningful competitive risk.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares are under pressure despite an earnings beat and higher outlook, as traders focus on planned workforce cuts and restructuring tied to AI, alongside a slight revenue miss and unchanged adjusted earnings guidance. Bulls view the selloff as an overreaction, pointing to resilient card spending and credit quality.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,505.961324. The last known price of Zebec Network is 0.00185282 USD and is down -2.31 over the last 24 hours. It is currently trading on 133 active market(s) with $11,016,611.66 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Zebecs payroll and payments partnershipsespecially the MoneyGram/Stellar integration and reported Germany/AllUnity deploymentare fueling discussion, alongside unconfirmed speculation about Robinhood. Bulls see these developments as signs of growing adoption, while skeptics argue that partnerships have yet to translate into sustained ZBCN demand or stronger price performance.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons quarterly earnings beat, with unusually strong refining profits amid tight diesel supply and record U.S. refinery throughput, is driving attention. Traders are weighing the stronger cash flow and debt reduction against concerns that refining gains may be temporary, while some are also debating whether the recent rally has run too far.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000498 USD and is up 2.29 over the last 24 hours. It is currently trading on 729 active market(s) with $440,504,313.03 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPEs sharp swings and repeated struggles to hold above a key round-number level dominate the discussion, with traders watching technical support and resistance. Some see recent rebounds as a potential breakout and are buying dips, while others view them as temporary bounces amid broader crypto-market weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New PrTK05 data showing systemic T-cell activation and transient biodistribution and viral shedding has renewed attention on Candels CAN-2409 prostate-cancer program, with bulls viewing it as supportive of the planned BLA submission. Others question how much the biomarker findings add to clinical evidence and remain concerned about filing timing, management credibility, and potential dilution.

The move appears tied to investor attention around Candels SITC 2026 presentations, which highlighted immune-activation findings and survival observations across its clinical programs, including CAN-2409. Traders focused on the encouraging data, though some noted the presentations were not new controlled-trial survival results.

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next 

Equity

Moderna will report on Friday, while the SITC meeting will bring fresh cancer-treatment findings from Immunocore and Candel.

Dow, S&P 500, Nasdaq Futures Edge Higher After Fed Delivers Rate Hike: SPCX, CADL, SNAP, FLNC Stocks In Focus

The Federal Reserve On Wednesday hiked benchmark interest rates by 25 bps to a target range of 3.75% to 4.00%, in line with market expectations. 

The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux 

Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4

If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product. 


CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug —  Eyes $10–$16B Opportunity 

Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.


CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’

Candel Therapeutics announced the initiation of a Phase 3 trial evaluating lead therapy CAN-2409 in advanced non-small cell lung cancer patients.

CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish

Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.

Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Vertex will report results on Monday, putting Journavx and Casgevy sales and its $10 billion Crinetics acquisition in focus.</li><li>Pfizer and BioNTech report on Tuesday, with Pfizer’s newer medicines and recent cancer-treatment advances drawing attention.</li><li>Amgen reports Tuesday and Novo Nordisk follows on Wednesday, spotlighting MariTide’s development and Wegovy sales.</li></ul><p>Biotech stocks head into a busy earnings week after beating the broader market, with Pfizer, Novo Nordisk and Moderna set to report earnings alongside a fresh round of cancer-treatment data.&nbsp;</p><p>Healthcare and biotech rallied the previous week, with the&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> gaining 5%, the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> climbing 4%, and the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rising 3%. Comparatively, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> fell 0.6%, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> dropped 2%.</p><p><img src="https://news.stocktwits-cdn.com/koyfin_20261102_072345224_2e2499ab82.png" alt="koyfin_20261102_072345224.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>What To Watch</td></tr><tr><td>Nov.2</td><td>VRTX</td><td>Q3 results</td></tr><tr><td>Nov.3</td><td>PFE / AMGN / BNTX / MDGL</td><td>Q3 results</td></tr><tr><td>Nov.3</td><td>SITC</td><td>Regular abstracts become public&nbsp;</td></tr><tr><td>Nov.4</td><td>NVO</td><td>Q3 results</td></tr><tr><td>Nov.4 - Nov.8</td><td>SITC</td><td>Cancer-immunotherapy meeting in Phoenix</td></tr><tr><td>Nov.5</td><td>IOVA</td><td>Q3 results</td></tr><tr><td>Nov.6</td><td>MRNA</td><td>Q3 results</td></tr><tr><td>Nov.6</td><td>SITC / IMCR / CADL</td><td>Late-breaking abstracts release; Immunocore and Candel presentations</td></tr><tr><td>Nov.7</td><td>IMCR / CADL</td><td>Immunocore oral presentation and Candel glioblastoma findings</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Vertex Looks Beyond Cystic Fibrosis</strong></h2><p>Vertex Pharmaceuticals will report results on Monday after the close, with investors looking for more growth from medicines outside its core cystic-fibrosis business.</p><p>Its non-opioid pain drug Journavx brought in $49.6 million in second-quarter sales, while gene-editing treatment Casgevy generated $76.4 million. In August, Vertex raised its full-year revenue forecast to $13.1 billion to $13.2 billion, including at least $500 million from the two drugs. That forecast did not include its $10 billion acquisition of Crinetics Pharmaceuticals, completed Sept.1. The deal added Palsonify, a once-daily pill for acromegaly, a disorder caused by excess growth hormone.&nbsp;</p><h2 class="st-heading-2"><strong>Pfizer Puts Its Cancer Business To The Test</strong></h2><p>Pfizer (PFE) will report on Tuesday, after a busy week for its cancer business. The FDA cleared Talzenna plus Xtandi for earlier use in metastatic prostate cancer with certain DNA-repair gene mutations. The next day, Pfizer said Elrexfio helped patients live longer without their multiple myeloma worsening in a Phase 3 trial against standard treatments. Researchers are still collecting data to determine its effect on overall survival.</p><p>For the earnings report, the question is whether newer medicines can keep making up for weaker COVID-related sales. Revenue from Pfizer’s launched and acquired products grew 18%, excluding currency effects, in the second quarter, helping the company raise the midpoint of its annual revenue forecast by $500 million.</p><p>BioNTech, Pfizer’s COVID-vaccine partner, also reports Tuesday.</p><h2 class="st-heading-2"><strong>Amgen And Novo Bring Obesity Back Into View</strong></h2><p>Amgen (AMGN) will report on Tuesday after the close, with an update on its obesity drug MariTide among the items to watch. Its Phase 3 Maritime program is studying weight management as well as cardiovascular disease, heart failure and sleep apnea. A separate trial is testing injections every eight weeks or quarterly in patients switching from weekly Tirzepatide or Semaglutide. Less frequent dosing could give patients another reason to choose the treatment if it wins approval.</p><p>Novo Nordisk (NVO) will report on Wednesday, with sales of the Wegovy pill and higher-dose injection offering a check on demand. Weekly U.S. prescriptions for the pill topped 265,000 by mid-July. Novo raised its outlook in August, though it still expected adjusted sales and operating profit to range from a 6% decline to no growth, excluding currency effects.</p><p>Madrigal Pharmaceuticals (MDGL) also will report on Tuesday, giving investors a look at demand for its liver-disease drug Rezdiffra.</p><h2 class="st-heading-2"><strong>Iovance Balances Melanoma Sales With Lung-Cancer Plans</strong></h2><p>Iovance Biotherapeutics (IOVA) will report on Thursday. Investors will get an update on Amtagvi, a treatment that uses patients’ own immune cells to fight advanced melanoma, as the company works to expand into lung cancer.</p><p>Results released last month showed a 24.6% response rate among 69 previously treated lung-cancer patients. That rose to 59.1% in a 22-patient subgroup identified using tumor genetics and smoking history. Iovance plans to begin enrolling its Positility cohort in November to test that selection strategy prospectively. A filing for Lifileucel in the broader previously treated lung-cancer population is planned for 2027.</p><h2 class="st-heading-2"><strong>Moderna’s Earnings Go Beyond Vaccine Sales</strong></h2><p>Moderna (MRNA) will report on Friday, with investors weighing seasonal vaccine sales alongside progress on its personalized cancer vaccine. The company previously targeted up to 10% revenue growth for 2026 and expected about 55% of its second-half revenue to come in the third quarter.</p><p>Its update could also bring more detail on regulatory plans for Intismeran Autogene. Last month, Moderna and Merck (MRK) said the experimental vaccine, combined with Merck’s immunotherapy Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone in a Phase 3 trial. Overall-survival data are still being collected.</p><h2 class="st-heading-2"><strong>New Cancer Findings Arrive At SITC</strong></h2><p>The Society for Immunotherapy of Cancer’s annual meeting and pre-conference programs run Nov.4-Nov.8 in Phoenix. Regular research abstracts become public on Tuesday, followed by late-breaking findings on Friday.</p><p>Immunocore (IMCR) will present early results for Brenetafusp alone and with Kimmtrak in metastatic uveal melanoma, an eye cancer that has spread. Both drugs help direct immune cells called T cells to attack cancer. Additionally, Candel Therapeutics (CADL) will present lung-cancer findings Friday in patients whose disease progressed despite earlier immunotherapy. On Saturday, it will share early findings in recurrent glioblastoma, an aggressive brain cancer.</p><h2 class="st-heading-2"><strong>Inovio Gets FDA Approval As Agios Faces A Delay</strong></h2><p>Two names from last week’s FDA watchlist head into November with different outcomes: an approval for Inovio Pharmaceuticals (INO) and a longer wait for Agios Pharmaceuticals (AGIO).</p><p>On Friday, the FDA granted accelerated approval to Inovio’s Voceryq, formerly INO-3107, for adults with recurrent respiratory papillomatosis. The rare HPV-related disease causes recurring airway growths that can require repeated surgery.&nbsp;</p><p>Meanwhile, the FDA extended its review of Agios’ Mitapivat for sickle cell disease to Feb.1, 2027, from Nov.1. The agency is considering whether a risk-management program is needed and classified additional safety information as a major amendment, triggering the three-month extension.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-musk-tsmc-terafab-talks-capex-efficiency-greatly-underestimated/cNG9KfcR92f">SPCX Stock Jumps Overnight: Musk Reportedly Revives TSMC Terafab Talks — Says Capex Efficiency Is ‘Greatly Underestimated’&nbsp;</a></p>

Biotech Stocks Beat The S&P500 – Can Pfizer, Novo And Moderna Earnings Keep The Rally Going?

Agios Pharmaceuticals Inc

AMGEN Inc.

BioNTech SE - ADR

iShares Biotechnology ETF

Immunocore Holdings PLC - ADR

Inovio Pharmaceuticals Inc

Iovance Biotherapeutics Inc

Madrigal Pharmaceuticals Inc

Merck & Co Inc

Moderna Inc

Novo Nordisk A/S

Pfizer Inc

Vertex Pharmaceuticals, Inc.

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Investors are closely analyzing new SITC conference biomarker data as a pivotal indicator for BLA submission confidence.

Traders are monitoring unusual dark pool activity and volume spikes to anticipate potential upside against manipulative algorithmic selling.

Discussions are heating up regarding the multi-tumor utility of the proprietary viral platform in treating prostate, lung, and brain cancers.

Market sentiment remains laser-focused on the anticipated BLA filing, with enthusiasts betting on a massive catalyst move in Q4.

Current Price	$8.75
Prev Close	$8.04
Open	$8.24
Dividend Yield	0.00%
50-Day Moving Average	$10.20
Beta	1.64
Avg. Volume	953,816.10
PE Ratio	-6.21

52-Week High	$14.00
52-Week Low	$4.35
Market Capitalization	$669.54M
EPS (Annual)	-$0.721
Price to Book	5.28
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CADL Fundamentals